Pharmaceutical

BioVaxys and Sona partner to develop cancer therapeutics

BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform (DPX) with THT.

May 10, 2025 - 06:00
BioVaxys and Sona partner to develop cancer therapeutics
BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform (DPX) with THT.
Read the original article

Tags:

Previous Article

VC firm Vivo Capital outlays $740m for biotech investment

Next Article

Bisphosphonate Timing Influences Jaw Osteonecrosis Risk

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ARS Pharma’s epinephrine nasal spray 1mg now available in US

ARS Pharma’s epinephrine nasal spray 1mg now available ...

May 8, 2025

STAT+: FDA cites Fresenius Kabi for contamination problems that CDC linked to deadly sepsis cases

STAT+: FDA cites Fresenius Kabi for contamination probl...

Oct 4, 2023

AbbVie achieves win for migraine prevention drug Aquipta in Europe

AbbVie achieves win for migraine prevention drug Aquipt...

Aug 18, 2023